Official Title
Expanded Access to Navitoclax
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available
Individual Patients
Myelofibrosis
Acute Lymphocytic Leukemia (ALL)
Lymphoblastic Lymphoma
Tumor

Drug: Navitoclax
Tablet, Oral
Other Name: ABT-263

Drug: Venetoclax
Tablet, Oral
Other Name: Venclexta
Other Name: ABT-199
Other Name: GDC-0199

Eligibility Gender
All
Eligibility Age
Minimum: 4 Years
Contacts

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

AbbVie Inc.
Study Director
AbbVie

NCT Number
Keywords
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary Myelofibrosis
Venetoclax
Navitoclax
Intervention Name
Navitoclax
Venetoclax